Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Impact of Age
Autologous hematopoietic cell transplantation (AHCT) has been shown to prolong survival in patients with multiple myeloma (MM), however adequate data is lacking in patients>70 years and less than 50 years of age. We retrospectively analyzed and compared the outcome of patients between the two age groups (>70 vs. ≤ 50 yrs.). Our study showed comparable outcomes between these two age groups.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D ’Souza, Parameswaran Hari Tags: Original Study Source Type: research